As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
Hetero Healthcare's Volga Division provides focused therapeutic solutions for patients managing Urology and Nephrology conditions, with a particular emphasis on CKD-related anaemia. Since its launch, the division primarily concentrates on treating anaemia caused by chronic kidney disease and emphasises Hetero's ongoing commitment to advancing speciality healthcare across the nation. Browse our product range for effective, dependable treatment options.
View by-
| Brand | Therapy Area | SKU |
|---|---|---|
| Anti Anaemic | ||
| Hetrose | Anti Anaemic | Hetrose 500Mg 10Ml Injection |
| Antibiotics | ||
| Hetnit | Antibiotics | Hetnit 100 mg Tablets |
| Anti BPH | ||
| Alfman | Anti BPH | Alfman 10 mg Tablets |
| Silorap | Anti BPH | Silorap 8 mg Capsules, Silorap D8 Tablets |
| Tamcuf | Anti BPH | Tamcuf-D Tablets |
| Cancer of Prostate | ||
| Ahabir | Cancer of Prostate | Ahabir 250 mg Tablets, Ahabir 500 mg Tablets |
| Bicatero | Cancer of Prostate | Bicatero 50 mg Tablets |
| Enzana | Cancer of Prostate | Enzana 40 mg Capsules |
| Chronic Kidney Disease | ||
| Darbelife | Chronic Kidney Disease | Darbelife 25 mcg Pfs Injection, Darbelife 40 mcg Pfs Injection, Darbelife 60 mcg Pfs Injection |
| Over Active Bladder | ||
| Vesifa | Over Active Bladder | Vesifa 5 mg Tablets |
| Renal Calculi | ||
| PEB-MB6 | Renal Calculi | PEB-MB6 Oral Solution |